ENLV Enlivex Therapeutics Ltd.

8.95
+0.65  (+8%)
Previous Close 8.3
Open 8.49
Price To Book 7.34
Market Cap 101,440,428
Shares 11,334,126
Volume 465,359
Short Ratio
Av. Daily Volume 89,035
Stock charts supplied by TradingView

NewsSee all news

  1. Enlivex Therapeutics Closes $8.0 Million Registered Direct Offering

    Nes-Ziona, Israel, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV), a clinical-stage immunotherapy company, today announced the closing of its previously announced registered direct offering

  2. Enlivex Therapeutics Announces $8.0 Million Registered Direct Offering

    Nes-Ziona, Israel, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV), a clinical-stage immunotherapy company, today announced that it has entered into definitive agreements with certain

  3. Enlivex Therapeutics Announces Plan for Increased Production Capacity of AllocetraTM in Preparation for Potential Treatment of Coronavirus (COVID-19) Patients with Organ Failure

    Nes-Ziona, Israel, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV), a clinical-stage immunotherapy company, today announced that it is initiating a plan to increase its manufacturing capacity

  4. Data On Enlivex's Allocetra-OTS Immunotherapy for Peritoneal Solid Tumors and for Prevention of GvHD Selected for Presentation at the Transplantation & Cellular Therapy Meetings Conference (TCT) in Orlando, Florida

    Nes-Ziona, Israel, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV), a clinical-stage immunotherapy company, today announced that the company was selected, for a scientific presentation of two

  5. Enlivex Therapeutics Ltd. Announces Withdrawal of Proposed Offering of Ordinary Shares

    Nes Ziona, Israel, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. ("Enlivex" or the "Company") (NASDAQ:ENLV) today announced that it has withdrawn its previously announced proposed underwritten public

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 trial to be initiated 2Q 2021.
Allocetra
GvHD - steroid refractory
Phase 2 trial to be initiated 1Q 2020. Phase 1b trial completed recruitment November 2019.
Allocetra
Prevention of cytokine storms in Sepsis
Phase 2/3 trial to be initiated 1Q 2020.
Allocetra
Prevention of GvHD & Transplant Complications

Latest News

  1. Enlivex Therapeutics Closes $8.0 Million Registered Direct Offering

    Nes-Ziona, Israel, Feb. 26, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV), a clinical-stage immunotherapy company, today announced the closing of its previously announced registered direct offering

  2. Enlivex Therapeutics Announces $8.0 Million Registered Direct Offering

    Nes-Ziona, Israel, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV), a clinical-stage immunotherapy company, today announced that it has entered into definitive agreements with certain

  3. Enlivex Therapeutics Announces Plan for Increased Production Capacity of AllocetraTM in Preparation for Potential Treatment of Coronavirus (COVID-19) Patients with Organ Failure

    Nes-Ziona, Israel, Feb. 24, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV), a clinical-stage immunotherapy company, today announced that it is initiating a plan to increase its manufacturing capacity

  4. Data On Enlivex's Allocetra-OTS Immunotherapy for Peritoneal Solid Tumors and for Prevention of GvHD Selected for Presentation at the Transplantation & Cellular Therapy Meetings Conference (TCT) in Orlando, Florida

    Nes-Ziona, Israel, Feb. 20, 2020 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV), a clinical-stage immunotherapy company, today announced that the company was selected, for a scientific presentation of two

  5. Enlivex Therapeutics Ltd. Announces Withdrawal of Proposed Offering of Ordinary Shares

    Nes Ziona, Israel, Nov. 21, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. ("Enlivex" or the "Company") (NASDAQ:ENLV) today announced that it has withdrawn its previously announced proposed underwritten public

  6. Enlivex Therapeutics Ltd. Announces Proposed Offering of Ordinary Shares

    Nes Ziona, Israel, Nov. 20, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. ("Enlivex" or the "Company") (NASDAQ:ENLV) today announced that, subject to market and other conditions, it intends to offer and sell

  7. Enlivex Therapeutics Completes Recruitment In Phase Ib Trial Evaluating Safety And Efficacy Of Universal Off-The-Shelf Allocetra In Patients With Severe Sepsis

    Nes Ziona, Israel, Nov. 18, 2019 (GLOBE NEWSWIRE) --   Enlivex Therapeutics Ltd. (NASDAQ:ENLV), a clinical-stage immunotherapy company, today reported completion of patient recruitment into the Company's Phase Ib

  8. Enlivex Therapeutics To Present At The 10th Annual Jefferies 2019 London Healthcare Conference

    Nes-Ziona, Israel, Nov. 12, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV), a clinical-stage immunotherapy company, today announced that company management will make a corporate presentation and host

  9. Enlivex Therapeutics Announces Positive Interim Safety and Efficacy Data From Ongoing Trial of Off-The-Shelf Allocetra in Patients with Severe Sepsis

    Nes Ziona, Israel, Nov. 04, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV), a clinical-stage immunotherapy company, today announced positive interim efficacy data from the Company's ongoing Phase Ib

  10. Enlivex Announces Appointment of New Chief Executive Officer

    Nes-Ziona, Israel, Oct. 24, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced the appointment of Dr. Oren Hershkovitz as Chief Executive Officer, effective

  11. Preclinical Data Indicating Allocetra-OTS As Potential Therapy For Prevention Of Organ Failure And Mortality Associated with Severe Sepsis Selected For Presentation At The XVIIIth Congress Of the European and Int'l Shock Societies

    Nes-Ziona, Israel, Oct. 10, 2019 (GLOBE NEWSWIRE) --  Enlivex Therapeutics Ltd. (NASDAQ:ENLV), a clinical-stage immunotherapy company, today announced today that the European and Int'l Shock Societies  selected,

  12. European Patent Office Grants New Patent Covering Enlivex's Allocetra™ Immunotherapy Treatment

    Nes-Ziona, Israel, Oct. 08, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced that the European Patent Office granted a new patent (#EP 2 929 015 B1) covering

  13. Data On Combination Of Allocetra-OTS Immunotherapy and CAR-T Therapy Designed For Treating Solid Tumors Selected For Presentation At The European Molecular Biology Organization's 2019 Cell Death in Immunity and Inflammation Workshop

    Nes-Ziona, Israel, Oct. 07, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics Ltd. (NASDAQ:ENLV), a clinical-stage immunotherapy company, today announced that the European Molecular Biology Organization (EMBO) selected,

  14. First Data On Combination Of Enlivex's Allocetra-OTS Immunotherapy and CAR-T Therapy Designed For Treating Solid Tumors Revealed At The Joint IIS-ISCR Special 2019 Conference

    Nes-Ziona, Israel, Sept. 23, 2019 (GLOBE NEWSWIRE) --  Enlivex Therapeutics Ltd. (NASDAQ:ENLV), a clinical-stage immunotherapy company, today announced the first presentation of its preclinical studies, which were

  15. New Patent Covering Enlivex's AllocetraTM Immunotherapy Was Allowed By The Israeli Patent Authority

    Nes-Ziona, Israel, Sept. 09, 2019 (GLOBE NEWSWIRE) -- Enlivex Therapeutics, Ltd., a clinical-stage immunotherapy company, today announced that the Israeli Patent Authority issued a notice of allowance for a patent